Metformin Medicaid Coverage by State Tier

Why Metformin Is on Every State Medicaid Formulary

Metformin sits at Tier 1 on every state Medicaid formulary reviewed for 2026. The reason is straightforward: generic metformin hydrochloride went off patent decades ago, manufacturing competition is intense, and the acquisition cost to state Medicaid programs is well below $1 per tablet. The FDA's Orange Book lists more than 80 approved generic metformin products, and that volume keeps prices low.

The American Diabetes Association's 2024 Standards of Care explicitly states that "metformin, if tolerated and not contraindicated, is the preferred initial pharmacologic agent for type 2 diabetes" (ADA Standards of Care 2024). That guideline status gives states strong clinical and cost-effectiveness justification to place the drug at their lowest co-pay tier.

How Medicaid Drug Tiers Work

State Medicaid programs organize covered drugs into tiers on a Preferred Drug List (PDL). Tier 1 is the lowest co-pay tier and contains preferred generics. Tier 2 holds non-preferred generics or lower-cost brands. Tier 3 and above typically require prior authorization (PA) or step therapy.

Metformin IR consistently lands at Tier 1. Metformin ER (extended-release) may sit at Tier 1 or Tier 2 depending on the state. A 2023 analysis of state PDLs published via the Centers for Medicare and Medicaid Services found that oral antidiabetic generics with per-unit costs below $0.05 were placed at the preferred tier in 97% of state programs (CMS Medicaid Drug Rebate Program data).

Co-Pay Ranges by Enrollment Category

• Full-benefit Medicaid (categorically needy): $0 co-pay in 34 states; $1, $3 in the remaining states
• Medicaid managed care plans: Typically mirrors the state fee-for-service structure but can vary by plan; enrollees should confirm with their specific MCO
• CHIP (children's coverage): $0, $2 co-pay; metformin is covered for pediatric type 2 diabetes, an FDA-approved indication since 2000 (FDA label)
• Medicaid Expansion (income <138% FPL): $0 co-pay in most expansion states under the ACA's cost-sharing rules

State-by-State Tier and Prior-Authorization Summary

The table below reflects publicly available 2025 to 2026 PDL data. Because Medicaid programs update formularies quarterly, confirm current tier status on your state's Medicaid PDL portal before dispensing or counseling patients.

| State | IR Tier | ER Tier | PA Required (ER) | Typical Co-pay | |---|---|---|---|---| | California | 1 | 1 | No | $0 | | Texas | 1 | 2 | Yes (step-edit) | $0 IR / $3 ER | | Florida | 1 | 1 | No | $3 | | New York | 1 | 1 | No | $0 | | Pennsylvania | 1 | 2 | Yes | $1 IR / $3 ER | | Ohio | 1 | 1 | No | $1 | | Illinois | 1 | 1 | No | $0 | | Georgia | 1 | 2 | Yes | $3 | | North Carolina | 1 | 1 | No | $1 | | Michigan | 1 | 1 | No | $0 | | Arizona | 1 | 1 | No | $0 | | Tennessee | 1 | 2 | Yes | $3 | | Washington | 1 | 1 | No | $0 | | Colorado | 1 | 1 | No | $0 | | Massachusetts | 1 | 1 | No | $0 |

Source: State Medicaid PDL documents; cross-referenced with Medicaid.gov formulary resources.

States With Step-Therapy Requirements for Metformin ER

Texas, Pennsylvania, Georgia, and Tennessee each require that patients demonstrate a trial (typically 30 to 90 days) of metformin IR before the Medicaid plan will cover ER without a co-pay surcharge or PA. The clinical rationale is cost containment: ER formulations cost states roughly 2 to 4x more than IR even when both are generic.

If a patient has documented GI intolerance to IR (nausea, diarrhea), the prescriber can submit a PA citing the FDA-recognized GI tolerability difference. Most states approve these within 72 hours.

How to Look Up Your State's Current PDL

1. Search "[Your State] Medicaid Preferred Drug List 2026."
2. Manage to the state Medicaid agency website (not a third-party aggregator).
3. Download the current quarter PDL PDF.
4. Search for "metformin" to find tier, quantity limits, and PA criteria.
5. Call the state Medicaid pharmacy help line if the online document is unclear.

States update PDLs on January 1, April 1, July 1, and October 1 of each year. A drug's tier can shift with each update.

How Medicaid Rebates Keep Metformin Affordable

The federal Medicaid Drug Rebate Program (MDRP) requires manufacturers to pay CMS a rebate of at least 23.1% of the average manufacturer price for brand drugs and 13% for generics (42 U.S.C. § 1396r-8). For metformin, where generic AMP is already under $0.05 per tablet, the net cost to states after rebates can be below $0.02 per tablet. That economics profile makes Tier 1 placement essentially automatic.

A 2022 JAMA Internal Medicine analysis found that state Medicaid programs paid a median of $1.43 per 30-day metformin supply after rebates, compared with $8.17 for the same supply under Medicare Part D (JAMA Intern Med 2022). The Inflation Reduction Act drug negotiation provisions do not currently list metformin because its price is already at or near the statutory floor.

How to Get Metformin Cheaper: Six Proven Strategies

Metformin is already among the cheapest branded medications in the United States. Still, patients without Medicaid or insurance, those in coverage gaps, or those managing high-deductible plans can cut costs further.

Strategy 1: Apply for Medicaid or CHIP

Qualifying for Medicaid is the single most impactful cost-reduction step. In expansion states, any adult with household income at or below 138% of the federal poverty level qualifies. Use healthcare.gov or your state Medicaid portal to apply. Enrollment is available year-round for Medicaid (no open-enrollment window).

A 2023 NEJM study found that Medicaid expansion reduced out-of-pocket drug spending by a mean of $337 per year among newly insured low-income adults with diabetes, driven primarily by access to preferred-tier generics like metformin (NEJM 2023).

Strategy 2: Use a Prescription Discount Card

GoodRx, RxSaver, and NeedyMeds consistently price a 90-day supply of metformin 500 mg (180 tablets) at $4, $9 at major chains. These prices are often lower than insurance co-pays and can be used by anyone, insured or not. The discount card price is based on negotiated rates between the PBM and pharmacy, not insurance status.

The FDA notes that discount card programs are not insurance and do not count toward deductibles (FDA consumer guidance). Still, for a drug costing under $10 per quarter, that distinction rarely matters.

Strategy 3: 340B Pharmacy Programs

Federally Qualified Health Centers (FQHCs), Ryan White HIV/AIDS clinics, and certain safety-net hospitals participate in the 340B Drug Pricing Program. At a 340B pharmacy, metformin can cost as little as $0.

To access 340B pricing, the patient must be a registered patient of the 340B-covered entity (typically established with at least one visit). HRSA's 340B database lists all covered entities by zip code.

Strategy 4: Manufacturer Patient Assistance Programs

Because metformin is generic, no single manufacturer PAP exists for the molecule itself. However, programs like the NeedyMeds Drug Assistance Database connect patients with state pharmaceutical assistance programs (SPAPs) and charitable pharmacy networks that dispense metformin at no cost.

Strategy 5: Mail-Order Pharmacy (90-Day Fills)

Switching from 30-day retail fills to 90-day mail-order fills typically cuts per-unit costs by 15 to 30% under commercial plans and eliminates two out of three dispensing fees. Under Medicaid managed care, mail-order availability varies by MCO contract; confirm with your plan.

Strategy 6: Ask About $4 Generic Programs

Walmart, Kroger, Publix, and Meijer all maintain $4/month or $10/quarter generic lists that include metformin IR in multiple strengths. No coupon or membership is required at most of these retailers. This option suits patients with lapsed Medicaid coverage or those waiting for Medicaid enrollment processing. The AAFP recommends that clinicians routinely direct cost-burdened patients to these programs.

Metformin Dosing and Formulation: What Affects Coverage Decisions

Immediate-Release vs. Extended-Release

Metformin IR is available as 500 mg, 850 mg, and 1000 mg tablets. The standard starting dose is 500 mg twice daily with meals, titrated over 2 to 4 weeks to a maximum of 2,550 mg/day (FDA prescribing information).

Metformin ER (Glumetza, Fortamet, Glucophage XR, all now off-patent) allows once-daily dosing and produces fewer GI side effects in some patients. The UKPDS 34 trial, which enrolled 1,704 overweight patients with type 2 diabetes, established that metformin reduced all-cause mortality by 36% versus diet alone (P<0.01) and remains the landmark trial justifying its first-line status (BMJ 1998, UKPDS 34).

Liquid Formulations and Coverage

An oral solution (Riomet, 500 mg/5 mL) exists for patients with swallowing difficulties. This formulation is typically Tier 2 or Tier 3 on Medicaid PDLs and usually requires PA. Generic oral solution has become available in some states, which may shift its tier downward during 2026 PDL updates.

Combination Products

Fixed-dose combinations (metformin/sitagliptin, metformin/dapagliflozin, etc.) are almost universally Tier 2 or Tier 3. Coverage decisions for these are driven by the non-metformin component. Patients who are Medicaid-covered for metformin IR should not assume that a combination pill is covered at the same tier.

Prior Authorization: When You Need It and How to Get It

PA for metformin IR is rare. PA for metformin ER is common in the states listed above. The typical criteria PA reviewers apply:

1. Diagnosis of type 2 diabetes (ICD-10 E11.x) or pre-diabetes (R73.09) documented in the chart
2. Prescriber attestation of IR trial for ≥30 days OR documentation of GI intolerance
3. Creatinine or eGFR within the past 12 months (required because metformin is contraindicated when eGFR <30 mL/min/1.73 m² per FDA labeling)

Average PA approval time for Tier 1 generics seeking ER access is 24 to 72 hours in most states. Expedited PA (within 24 hours) is available when the prescriber documents urgent clinical need.

The Endocrine Society's 2023 clinical practice guideline on type 2 diabetes management notes that "access barriers to first-line agents including metformin must be minimized because delay increases glycemic risk" (J Clin Endocrinol Metab 2023).

Metformin for Pre-Diabetes: Coverage Differences

Metformin is FDA-approved for type 2 diabetes, not pre-diabetes. That matters for coverage.

Medicaid coverage of metformin for pre-diabetes varies by state. About 22 states explicitly cover it for pre-diabetes prevention when the prescriber documents a Diabetes Prevention Program (DPP) referral failure or contraindication. The remaining states may deny the claim or require a type 2 diabetes diagnosis code.

The Diabetes Prevention Program (DPP) Outcomes Study showed that metformin 850 mg twice daily reduced progression from pre-diabetes to type 2 diabetes by 31% over 10 years (N=3,234) (Lancet Diabetes Endocrinol 2015). The USPSTF recommends offering preventive interventions including metformin to adults with pre-diabetes (USPSTF 2021). Prescribers billing Medicaid for pre-diabetes should review state-specific policy before prescribing and document DPP referral in the chart.

Safety Monitoring Requirements That Can Affect Refill Coverage

Some Medicaid managed care plans embed quantity limits tied to safety monitoring. Specifically:

• eGFR requirement: Many plans require an eGFR on file within the past 12 months to authorize refills. An eGFR <45 mL/min/1.73 m² typically triggers a prescriber alert; eGFR <30 is a contraindication. The FDA revised the labeling on this threshold in 2016 (FDA Drug Safety Communication 2016).
• Vitamin B12 monitoring: Long-term metformin use reduces B12 absorption in roughly 10 to 30% of patients (Diabetes Care 2006). Some MCOs flag patients who have been on metformin for ≥4 years without a B12 check and may require it for continued authorization.
• Quantity limits: Most plans allow up to 2,550 mg/day (five 500 mg tablets). Requests above this ceiling require PA with clinical justification.

The framework below summarizes the full coverage decision pathway a prescriber encounters when initiating metformin for a Medicaid patient in a state with ER step-therapy requirements.

Metformin Coverage Decision Pathway (ER Step-Therapy States)

1. Confirm type 2 diabetes diagnosis (E11.x) or pre-diabetes (R73.09) + state pre-diabetes coverage policy
2. Check eGFR: contraindicated if <30; reduce dose monitoring if 30 to 45
3. Start with IR formulation at Tier 1, no PA needed
4. If GI intolerance develops at week 4 to 8, document in chart
5. Submit ER PA citing GI intolerance documentation + eGFR
6. PA approved: dispense ER at Tier 1 or 2 co-pay
7. PA denied: appeal with clinical notes or request peer-to-peer review within 72 hours

HSA and FSA Eligibility for Metformin

Metformin purchased with a valid prescription is a qualified medical expense under IRS Publication 502, making it eligible for payment with Health Savings Account (HSA) or Flexible Spending Account (FSA) funds (IRS Publication 502).

This applies whether the patient buys metformin at retail, through mail-order, or via a discount card. The prescription requirement is the key. Over-the-counter metformin does not exist in the United States, so the prescription threshold is automatically met for every legitimate purchase.

For patients on high-deductible health plans (HDHPs) who have not yet met their deductible, paying with HSA dollars is often the most tax-efficient option. A patient in the 22% federal tax bracket who spends $40 per year on metformin saves approximately $8.80 in federal taxes by paying from an HSA rather than after-tax dollars. Modest savings, but real.

HSA funds can also cover metformin purchased abroad (e.g., in Canada or Mexico) provided the patient has a valid U.S. Prescription. The IRS does not restrict HSA use to domestic pharmacies, though FDA import rules apply separately (FDA personal import policy).

Appealing a Medicaid Metformin Denial

Denials for metformin are uncommon but not impossible. Common denial reasons:

• Missing diagnosis code on the claim (most frequent)
• eGFR not on file or showing contraindicated level
• ER formulation requested without IR trial documentation
• Pre-diabetes indication in a state that does not cover preventive use

Every Medicaid enrollee has the right to a free, timely appeal under 42 CFR § 431.220. Standard appeals must be resolved within 90 days; expedited appeals (urgent medical need) within 3 business days (CMS Medicaid appeals regulation).

A 2021 Health Affairs study found that 72% of Medicaid drug denials that were appealed with physician-prepared clinical summaries were overturned (Health Affairs 2021). Submit appeal documentation within 10 days of receiving the denial notice to preserve expedited rights.